Updated:
Famy Care
The Taparia family office invests tech and healthcare capital from Palo Alto and Mumbai, built from the sale of Famy Care's generics business to Mylan.
Famy Care
The Taparia family's investment office grew out of Famy Care Ltd., the women's health pharmaceutical company founded in 1985 that became a top global supplier of generic oral contraceptives. A watershed 2015 deal sold the generics business to Mylan for roughly $750 million, per pharmaceutical trade reports, crystallizing liquidity that the family redeployed through a formal family office structure. The office now operates independently of the operating business, with footprints in Palo Alto, Mumbai, and Kolkata. The investment strategy spans direct venture, growth equity, and select fund commitments, with a weighting toward healthcare technology and enterprise software. The office has backed digital health platforms that align with the family's legacy expertise in pharmaceutical distribution. Portfolio interests have extended into climate technology and enterprise SaaS, with the US and India as primary geographic theaters. The Palo Alto office sources Silicon Valley deal flow while the Mumbai office evaluates Indian healthtech and deep-tech opportunities, creating a bilateral pipeline that few family offices replicate. The office maintains a deliberately low profile — no public website, no press releases, no fund marketing — characteristic of liquidity-event family offices that prioritize discretion over brand-building. The multi-city structure suggests a team capable of evaluating deals across regulatory regimes. Co-investment relationships are cultivated privately, typically with other single-family offices and specialized venture firms rather than through public syndicates. The defining structural feature is the bridge mandate: the Taparia office uses the family's pharmaceutical credibility to diligence healthcare investments in India that US co-investors cannot easily reach, while offering Indian startups a pathway to US market validation. This bilateral arbitration function — underwriting risk in one market with expertise earned in the other — is not easily replicated by a conventional venture fund.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Additional offices
Mumbai, India · Kolkata, India
Sector focus
Frequently asked questions
What is the wealth origin of the Famy Care family office?
The underlying capital comes from Famy Care Ltd., a women's healthcare and generic pharmaceutical company founded by the Taparia family in 1985. The firm grew into one of the world's largest suppliers of generic oral contraceptives, exporting to over 100 countries. In 2015, the family sold the generics business to Mylan in a transaction valued at approximately $750 million, which generated the liquidity that funds the office's current investment activities.
How does the office's dual-city structure influence investment decisions?
The Palo Alto office sources early-stage technology and healthcare deals in Silicon Valley, while the Mumbai office evaluates Indian healthtech and enterprise opportunities. The family's pharmaceutical background gives them an underwriting edge in Indian healthcare, where distribution and regulatory expertise are hard to import. This bilateral setup lets the office diligence Indian companies with US-market sophistication and connect US portfolio companies to Indian manufacturing and distribution channels.
Does Famy Care's family office take outside capital or operate as a multi-family office?
The office is structured as a single-family office managing Taparia family capital. There is no public evidence of external LP relationships, fund vehicles, or multi-family office branding. The family has not opened the platform to other Indian pharmaceutical entrepreneur families, though private co-investment relationships with peer single-family offices are common in this segment.
Which sectors does the office actively invest in?
Healthcare technology and digital health form the core mandate, reflecting the family's pharmaceutical operating background. The office also reviews enterprise software, climate technology, and select deep-tech opportunities. Investments typically span pre-seed through growth equity stages, with no publicly disclosed sector exclusions. Indian healthtech platforms with cross-border distribution potential are a recurring theme.
How is the investment office governed relative to the original operating business?
Following the 2015 Mylan sale, the family separated the investment office from any residual operating assets. The investment team operates independently from Famy Care's legacy pharmaceutical manufacturing, which was largely divested in the transaction. Governance and investment committee details remain private, consistent with the office's no-website, no-press posture.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: